Physician profile
Peter Lim
NPI 1407891534
$440,678.92
in general payments reported to CMS, 2019-2025
25 companies · $81K in 2025
The $81K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91K · 2020: $44K · 2021: $18K · 2022: $97K · 2023: $76K · 2024: $34K · 2025: $81K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $79K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $75K · Travel and Lodging: $31K · Food and Beverage: $4,457 · Consulting Fee: $555 · Gift: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $78,886.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $75,375.01 |
| Travel and Lodging | $30,547.12 |
| Food and Beverage | $4,457.27 |
| Consulting Fee | $555.00 |
| Gift | $176.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $432,109.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $4,207.46 | 2019-2024 | Lynparza |
| Momentis Surgical INC. | $1,692.40 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $1,434.92 | 2023 | Xpovio |
| Eisai INC. | $258.47 | 2021-2025 | |
| Baxter Healthcare | $123.81 | 2022 | |
| Seagen INC. | $119.27 | 2022-2025 | |
| Glaxosmithkline, LLC. | $118.29 | 2025 | Jemperli |
| Minerva Surgical, INC | $104.53 | 2022 | |
| Merck Sharp & Dohme LLC | $71.84 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $71.27 | 2021-2022 | |
| Abbvie INC. | $66.58 | 2021-2024 | |
| Medtronic, INC. | $50.00 | 2022 | |
| Conmed Corporation | $41.67 | 2022 | |
| Axonics, INC. | $40.74 | 2023 | Axonics, Bulkamid |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $39.15 | 2019 | |
| Urgo Medical North America, LLC | $33.07 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Astellas Pharma US INC | $24.84 | 2024 | Veozah |
| Coherus Oncology, INC. | $24.09 | 2024 | |
| Organon LLC | $23.57 | 2024 | |
| Sumitomo Pharma America, INC. | $23.34 | 2025 | Myfembree |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.